1337 The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignancies

单克隆抗体 CD24型 离体 癌症研究 流式细胞术 体内 抗体 抗体依赖性细胞介导的细胞毒性 癌症 表位 体外 医学 分子生物学 免疫学 化学 生物 内科学 乳腺癌 生物化学 生物技术
作者
Peng Chen,Jishun Chen,Min Deng,Jiamei Luo,Yun Liu,Rong Hua Guo,Yunkai Zhang,Linjie Tian,Jay M. Mei,Bo Shan,Bing Hou
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A1488-A1491
标识
DOI:10.1136/jitc-2023-sitc2023.1337
摘要

Background CD24 is a small, highly glycosylated cell adhesion protein that functions as a novel ‘don’t eat me’ target in cancer, where it is the dominant innate immune checkpoint.1 Through its interaction with Siglec-10 expressed by tumor-associated macrophages, overexpression of CD24 on tumor cells prevents them from being engulfed by macrophages. Therapeutic antibodies blocking ‘don’t eat me’ signals exhibited potent preclinical and early clinical efficacy against solid tumor and hematological malignancies.2 ATG-031 is the first humanized anti-CD24 monoclonal antibody that enters clinic. Here, we present the ATG-031 preclinical results, including the pharmacology, pharmacodynamics (PD), pharmacokinetics (PK), and safety profiles. Methods The expression profile of CD24 was evaluated using IHC on a tissue microarray. ATG-031 underwent in vitro pharmacology assessments including but not limited to binding affinity, phagocytosis, receptor blockage, ex vivo cytokine release, and ADCC and CDC assays. In multiple syngeneic models, the in vivo efficacy of ATG-031 was evaluated. PD of ATG-031 was investigated using flow cytometry and single cell RNA sequencing of TILs isolated from MC38-hCD24 tumor samples following ATG-031 administration. ATG-031 and ATG-031-CM, a cynomolgus monkey surrogate antibody, were utilized for toxicology and PK studies in non-human primates (NHP). Results CD24 is extensively expressed in a variety of tumor types, whereas its distribution in normal tissues is limited (figure 1). ATG-031 binds to the protein backbone epitope of CD24 with affinity in the nM range against CD24 protein or tumor cells. With an EC50 in the sub-nM range, ATG-031 induces potent macrophage-dependent tumor cell phagocytosis. Phagocytosis induced by ATG-031 occurred within 5–10 minutes of incubation based on confocal imaging of live cells (figure 2). M2 macrophages begin to release M1-like cytokines upon phagocytosis. With an EC50 of 0.27nM, ATG-031 induced a potent ADCC effect against HT-29 tumor cells. ATG-031 exhibited potent antitumor activity in vivo as a single agent in syngeneic models such as MC38, CT26, and 4T1. It also demonstrated in vivo synergism with chemotherapies and checkpoint inhibitors. Treatment with ATG-031 significantly increased T cell-associated immune response at the cellular and single-cell transcriptome levels (figure 3). ATG-031 and ATG-031-CM were well tolerated in NHP, with toxicities consistent with the mechanism of action and target expression. Conclusions In preclinical studies, ATG-031 demonstrates potent antitumor activity, excellent safety and PK properties, which supports its further development in clinical trials. A phase I, multicentre, dose-escalating clinical trial is being developed to evaluate ATG-031 in patients with solid tumors and hematologic malignancies. References Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019 Aug;572(7769):392–396. Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol. 2022 Aug 17;15(1):110. Ethics Approval The protocol and any amendment(s) or procedures involving the care and use of animals in this study were reviewed and approved by the IACUC of CrownBio. All studies were conducted following an approved IACUC protocol. AUP NO.:2004–12-1465, 2004–12-1000; IACUC approval number: IACUC-2021-M-003
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
柚子完成签到,获得积分10
刚刚
molihuakai的应助被辣姜采纳,获得10
刚刚
小肥侠完成签到,获得积分10
1秒前
科研通AI6.4的应助被jqmiao采纳,获得10
1秒前
不吃香菜完成签到 ,获得积分10
1秒前
ding的应助被xjc23采纳,获得10
1秒前
Ginge完成签到,获得积分10
1秒前
1秒前
1秒前
坚定蘑菇发布了新的文献求助10
2秒前
gzy发布了新的文献求助10
3秒前
molihuakai的应助被juynlcs采纳,获得10
3秒前
chaiyuyang发布了新的文献求助30
3秒前
yukaaai完成签到,获得积分10
3秒前
xzy发布了新的文献求助10
3秒前
打打的应助被小高哇咔咔咔采纳,获得30
4秒前
4秒前
大土豆发布了新的文献求助10
4秒前
4秒前
4秒前
乔麦发布了新的文献求助10
5秒前
我是老大的应助被yan采纳,获得10
5秒前
feitanmbio发布了新的文献求助10
5秒前
5秒前
辞忧完成签到,获得积分10
6秒前
6秒前
KuangNK的应助被尘冀等待采纳,获得10
6秒前
6秒前
aa的应助被李燕伟采纳,获得10
7秒前
7秒前
ficus_min完成签到,获得积分10
7秒前
Jun的应助被fung采纳,获得10
7秒前
无极微光的应助被MSY采纳,获得20
7秒前
斯文败类的应助被冰糖采纳,获得10
8秒前
8秒前
8秒前
9秒前
乐乐的应助被文艺的梦秋采纳,获得10
9秒前
没问题完成签到,获得积分10
9秒前
chaiyuyang完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154217
求助须知:如何正确求助?哪些是违规求助? 9550722
关于积分的说明 21700876
捐赠科研通 7743358
什么是DOI,文献DOI怎么找? 3425651
关于科研通互助平台的介绍 2550897
邀请新用户注册赠送积分活动 2469372